Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Azeliragon + Methylprednisolone |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Azeliragon | PF-04494700|TTP488 | Azeliragon inhibits the interaction between receptor for advanced glycation end products (RAGE) and its ligands, potentially resulting in decreased tumor cell viability (PMID: 34763082). | ||
| Methylprednisolone | Artisone-Wyeth | 6alpha-Methylprednisolone |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05789589 | Phase Ib/II | Azeliragon + Methylprednisolone Azeliragon Azeliragon + Dexamethasone | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (ADORATION) | Recruiting | USA | 0 |